MX2012002449A - Terapia de reemplazo de enzimas con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa acida. - Google Patents

Terapia de reemplazo de enzimas con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa acida.

Info

Publication number
MX2012002449A
MX2012002449A MX2012002449A MX2012002449A MX2012002449A MX 2012002449 A MX2012002449 A MX 2012002449A MX 2012002449 A MX2012002449 A MX 2012002449A MX 2012002449 A MX2012002449 A MX 2012002449A MX 2012002449 A MX2012002449 A MX 2012002449A
Authority
MX
Mexico
Prior art keywords
acid sphingomyelinase
replacement therapy
dose escalation
enzyme replacement
treating acid
Prior art date
Application number
MX2012002449A
Other languages
English (en)
Other versions
MX356873B (es
Inventor
Edward H Schuchman
Robert J Desnick
Gerald F Cox
Laura P Andrews
James M Murray
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of MX2012002449A publication Critical patent/MX2012002449A/es
Publication of MX356873B publication Critical patent/MX356873B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)

Abstract

La invención se relaciona con la terapia de reemplazo de enzimas con aumento escalonado de la dosis que utiliza la esfingomielinasa ácida (ASM) para el tratamiento de sujetos humanos con deficiencia de esfingomielinasa ácida (ASMD) y, en particular, pacientes con manifestaciones no neurológicas de la enfermedad de Niemann Pick (NPD) y, en determinadas aplicaciones, con NPD tipo B.
MX2012002449A 2009-08-28 2010-08-28 Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida. MX356873B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
PCT/US2010/047057 WO2011025996A2 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (2)

Publication Number Publication Date
MX2012002449A true MX2012002449A (es) 2012-03-14
MX356873B MX356873B (es) 2018-06-18

Family

ID=43625265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002449A MX356873B (es) 2009-08-28 2010-08-28 Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.

Country Status (26)

Country Link
US (9) US8349319B2 (es)
EP (3) EP3998078A1 (es)
JP (7) JP5955219B2 (es)
KR (5) KR102608551B1 (es)
CN (3) CN106047835A (es)
AU (5) AU2010286550B2 (es)
BR (1) BR112012004377A2 (es)
CA (1) CA2773133A1 (es)
CL (1) CL2012000495A1 (es)
CY (1) CY1122128T1 (es)
DK (2) DK2470199T3 (es)
ES (2) ES2738859T3 (es)
FR (1) FR22C1062I2 (es)
HR (2) HRP20211992T1 (es)
HU (3) HUE057440T2 (es)
IL (3) IL300625A (es)
LT (2) LT2470199T (es)
MX (1) MX356873B (es)
NL (1) NL301211I2 (es)
PL (2) PL2470199T3 (es)
PT (2) PT3482767T (es)
RU (3) RU2569744C2 (es)
SI (2) SI3482767T1 (es)
TR (1) TR201911293T4 (es)
WO (1) WO2011025996A2 (es)
ZA (2) ZA201201435B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
SI2158322T1 (sl) 2007-06-06 2017-10-30 Genzyme Corporation Genska terapija za bolezni lizosomskega shranjevanja
HRP20211992T1 (hr) * 2009-08-28 2022-04-01 Icahn School Of Medicine At Mount Sinai Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze
US8882701B2 (en) * 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
EP2571997A2 (en) 2010-05-21 2013-03-27 Ohmx Corporation Enzymatic activity of psa as diagnostic marker for prostate cancer
PT2685986T (pt) 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
MX359328B (es) 2011-11-15 2018-09-25 Centogene Ag Metodo para el diagnostico de enfermedad de niemann-pick.
PT2854910T (pt) 2012-06-01 2020-05-06 Yeda Res & Dev Níveis de ceramida no tratamento e prevenção de infeções
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
HUE046113T2 (hu) 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TR201906195T4 (tr) * 2013-05-14 2019-05-21 Centogene Ag Niemann pıck hastalığının teşhisi için metot.
IL298675A (en) * 2013-06-07 2023-01-01 Genzyme Corp A marker for disorders of acid sphingomyelinase and its uses
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
JP7216075B2 (ja) * 2017-08-24 2023-01-31 サノフイ 酸性スフィンゴミエリナーゼ欠損症患者における骨状態異常の処置
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 酵素補充療法用酵素を含む融合タンパク質
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
EP4185267A1 (en) 2020-07-24 2023-05-31 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
ATE426031T1 (de) 1995-09-14 2009-04-15 Virginia Tech Intell Prop Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
AU776855B2 (en) 1998-12-23 2004-09-23 Boyce Thompson Institute For Plant Research Inc. Expression of immunogenic hepatitis B surface antigens in transgenic plants
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
AU2003224880A1 (en) 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
WO2004111198A2 (en) 2003-06-12 2004-12-23 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
BRPI0416434A (pt) 2003-11-25 2007-02-21 Sinai School Medicine métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina
US8119406B2 (en) 2004-10-13 2012-02-21 Protalix Ltd. System and method for production of antibodies in plant cell culture
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
EP1960534A4 (en) 2005-12-15 2009-03-25 Univ New York State Res Found ENZYMATIC METHODS FOR MEASURING THE SPHINGOMYLELIN AND PHOSPHATIDYLCHOLIN SHARE IN PLASMA AND TISSUE
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641070C (en) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
PL1988823T3 (pl) * 2006-02-09 2019-01-31 Genzyme Corporation Powolne dostarczanie dokomorowe
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
BR122020010601B8 (pt) 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
HRP20211992T1 (hr) * 2009-08-28 2022-04-01 Icahn School Of Medicine At Mount Sinai Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze
JP6175431B2 (ja) * 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法

Also Published As

Publication number Publication date
RU2015145255A3 (es) 2019-08-12
KR20230164773A (ko) 2023-12-04
US20220305091A1 (en) 2022-09-29
CN105999238A (zh) 2016-10-12
PT2470199T (pt) 2019-08-07
US20130078230A1 (en) 2013-03-28
CN106047835A (zh) 2016-10-26
AU2010286550B2 (en) 2016-05-19
DK3482767T3 (da) 2021-12-20
JP6952810B2 (ja) 2021-10-20
JP2024026214A (ja) 2024-02-28
US20160120957A1 (en) 2016-05-05
US10188705B2 (en) 2019-01-29
JP7395693B2 (ja) 2023-12-11
KR102608546B1 (ko) 2023-12-04
EP2470199A4 (en) 2013-03-27
TR201911293T4 (tr) 2019-08-21
AU2024201085A1 (en) 2024-03-07
JP2023012499A (ja) 2023-01-25
EP3482767B1 (en) 2021-10-06
KR20120081077A (ko) 2012-07-18
AU2020256322A1 (en) 2020-11-12
US8658162B2 (en) 2014-02-25
CA2773133A1 (en) 2011-03-03
JP2018076322A (ja) 2018-05-17
IL218324B (en) 2019-05-30
AU2018204156B2 (en) 2020-07-16
EP3998078A1 (en) 2022-05-18
US20210077593A1 (en) 2021-03-18
CY1122128T1 (el) 2020-11-25
WO2011025996A9 (en) 2011-08-25
BR112012004377A2 (pt) 2017-12-12
CN102596232A (zh) 2012-07-18
US20110052559A1 (en) 2011-03-03
ZA201201435B (en) 2020-05-27
AU2018204156A1 (en) 2018-06-28
JP5955219B2 (ja) 2016-07-20
ES2738859T3 (es) 2020-01-27
KR20200034828A (ko) 2020-03-31
KR20220104271A (ko) 2022-07-26
JP2022003065A (ja) 2022-01-11
KR102094253B1 (ko) 2020-03-31
HRP20211992T1 (hr) 2022-04-01
LT2470199T (lt) 2019-10-10
IL266915B2 (en) 2023-07-01
US20190151419A1 (en) 2019-05-23
JP7167281B2 (ja) 2022-11-08
EP2470199A2 (en) 2012-07-04
EP3482767A1 (en) 2019-05-15
HRP20191385T1 (hr) 2019-11-01
EP2470199B1 (en) 2019-05-22
US8709408B2 (en) 2014-04-29
US9655954B2 (en) 2017-05-23
IL266915B1 (en) 2023-03-01
RU2731616C2 (ru) 2020-09-07
RU2569744C2 (ru) 2015-11-27
FR22C1062I2 (fr) 2023-12-29
IL300625A (en) 2023-04-01
NL301211I2 (nl) 2023-02-02
PL2470199T3 (pl) 2019-11-29
AU2016216625B2 (en) 2018-07-05
AU2010286550A1 (en) 2012-03-15
RU2015145255A (ru) 2019-01-11
HUE057440T2 (hu) 2022-05-28
NL301211I1 (nl) 2022-12-28
AU2016216625A1 (en) 2016-09-15
JP6251307B2 (ja) 2017-12-20
PT3482767T (pt) 2021-12-29
LT3482767T (lt) 2022-01-10
JP2020090513A (ja) 2020-06-11
FR22C1062I1 (fr) 2023-02-03
KR102608551B1 (ko) 2023-12-04
RU2020128994A (ru) 2022-03-02
PL3482767T3 (pl) 2022-02-14
US20130078231A1 (en) 2013-03-28
SI3482767T1 (sl) 2022-03-31
US8349319B2 (en) 2013-01-08
KR20210107153A (ko) 2021-08-31
WO2011025996A3 (en) 2012-03-15
MX356873B (es) 2018-06-18
AU2020256322B2 (en) 2024-02-29
CL2012000495A1 (es) 2014-02-07
JP2016153408A (ja) 2016-08-25
HUE046598T2 (hu) 2020-03-30
US20180055916A1 (en) 2018-03-01
US20140335070A1 (en) 2014-11-13
DK2470199T3 (da) 2019-08-05
IL218324A0 (en) 2012-04-30
IL266915A (en) 2019-07-31
SI2470199T1 (sl) 2019-11-29
WO2011025996A2 (en) 2011-03-03
ZA201601362B (en) 2017-05-31
US9114139B2 (en) 2015-08-25
RU2012111823A (ru) 2013-10-10
HUS2200050I1 (hu) 2022-12-28
JP2013502933A (ja) 2013-01-31
ES2902229T3 (es) 2022-03-25

Similar Documents

Publication Publication Date Title
MX356873B (es) Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MX2019002669A (es) Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
EP2494059A4 (en) USE OF METHYSULFONYLMETHANE (MSM) FOR MODULATION OF MICROBIAL ACTIVITY
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
MX350046B (es) Tratamientos para trastornos gastrointestinales.
MX2013000319A (es) Tratamiento de transtornos cognitivos.
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
MX371198B (es) Terapia antidiabetica vasoprotectora y cardioprotectora.
CY1119845T1 (el) Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος
UA41106U (ru) Способ лечения гипостатической пневмонии у больных с хронической сердечной недостаточностью
UA44534U (ru) Способ лечения синдрома эйзенменгера
UA29611U (ru) Способ имплантации электродов для регистрации биоэлектрической активности базальных височных отделов головного мозга
UA106357C2 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: VERTEX PHARMACEUTICALS INCORPORATED.*

FG Grant or registration